Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott Labs marches toward new highs as it tackles coronavirus testing, and the earnings report is on deck. Here's a look at the charts for the stock. The action comes with the stock just off its ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Buy Abbott Labs on weakness to the annual and semiannual value levels at $84.46 and $82.77, respectively. Reduce holdings on strength to the quarterly risky level at $95.83. Abbott Laboratories ...

Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories launched its newest continuous glucose monitor in the U.S. on Thursday. The biosensor named Lingo is the first-ever targeted for people without diabetes. Please watch the video ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...